US20010036475A1 - Pharmaceutical tablets - Google Patents
Pharmaceutical tablets Download PDFInfo
- Publication number
- US20010036475A1 US20010036475A1 US09/881,285 US88128501A US2001036475A1 US 20010036475 A1 US20010036475 A1 US 20010036475A1 US 88128501 A US88128501 A US 88128501A US 2001036475 A1 US2001036475 A1 US 2001036475A1
- Authority
- US
- United States
- Prior art keywords
- wax
- bisphosphonic acid
- beeswax
- amino
- synthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *CC(*)(P(=O)(O)O)P(=O)(O)O Chemical compound *CC(*)(P(=O)(O)O)P(=O)(O)O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Definitions
- the present invention relates to novel pharmaceutical tablets. These tablets have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gastrointestinal effects. These compositions are useful for administering pharmaceutical active ingredients, such as bisphosphonates.
- the present invention solves this problem by providing a tablet formulation and process therefore that avoids such interaction between the bisphosphonic acid and the lactose in the formulation.
- the present invention provides a processing advantage since it requires only blending of the ingredients without granulation or addition of water prior to compression.
- intravenous administration is costly and inconvenient, especially when the patient must be given an intravenous infusion lasting several hours on repeated occasions.
- oral administration of the bisphosphonate is desired, relatively high doses must be administered to compensate for the low bioavailability from the gastrointestinal tract. To offset this low bioavailability, it is generally recommended that the patient take the bisphosphonate on an empty stomach and fast for at least 30 minutes afterwards.
- many patients find the need for such fasting on a daily basis to be inconvenient.
- enteric coated tablets To combat the premature release of active ingredient in the upper gastrointestinal tract, dosage forms have been developed to delay the release of the active ingredients after passage through the upper gastrointestinal tract and in some cases through the stomach, i.e., enteric coated tablets.
- enteric and completely coated tablets have disadvantages because in certain instances its undesirable or unnecessary for a medicament to be in a delayed release dosage form. Additionally, enteric and completely coated tablets reduce the bioavailability of the active ingredient.
- dosage forms that facilitate rapid esophageal transit, minimize or avoid the release of an active ingredient in the upper gastrointestinal tract, deliver the active ingredient to the stomach, and maintain the bioavailability of the active ingredient.
- the present invention solves this problem by providing a tablet formulation and process therefor that both facilitates esophageal transit and maintains the bioavailability of the active ingredient.
- the discontinuous wax polish of the present invention has surprisingly been found to be useful for administering active agents such as bisphosphonates. These tablets with a discontinuous wax polish have the advantage of providing rapid transit through the esophagus to minimize the occurrence of adverse effects.
- the discontinuous wax coating or polishing also has the advantage over enteric coated tablets of not interfering with the bioavailability of the active ingredient.
- the current invention provides a dosage form that eases and/or eliminates patient discomfort after dosing while maintaining the bioavailability of the active ingredient.
- the present invention relates to novel pharmaceutical compositions, particularly tablets. These compositions have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gastrointestinal effects. These compositions are useful for administering pharmaceutical active ingredients, such as bisphosphonates.
- the present invention relates to a pharmaceutical tablet, comprising:
- excipients from about 60 to 99.5% by weight of excipients, said excipients comprising a diluent selected from the group consisting of anhydrous lactose or hydrous fast flow lactose, or mixtures thereof, a binder, a disintegrant, a lubricant; and a wax.
- a diluent selected from the group consisting of anhydrous lactose or hydrous fast flow lactose, or mixtures thereof, a binder, a disintegrant, a lubricant; and a wax.
- the present invention relates to a process for the preparation of a pharmaceutical tablet comprising;
- the present invention relates to novel pharmaceutical compositions, particularly tablets, that are useful for administering pharmaceutical active ingredients, such as bisphosphonates.
- the compositions of the present invention are coated with a discontinuous wax polish that enables the compositions to have improved surface properties such as rapid esophageal transit of the composition, which reduces the potential for adverse gastrointestinal effects.
- the improved surface properties due to the discontinuous wax polish also enable the compositions to maintain the bioavailability of the active ingredient, thereby preserving the active ingredient's potency.
- the present invention is characterized by pharmaceutical compositions comprising from about 0.5 to 40% by weight of an active ingredient, said active ingredient being a bisphosphonic acid or a pharmaceutically acceptable salt or ester thereof; from about 60 to 99.5% by weight of excipients, said excipients comprising a diluent selected from the group consisting of anhydrous lactose or hydrous fast flow lactose, a binder, a disintegrant, a lubricant; and a discontinuous wax polish.
- the bisphosphonic acid or pharmaceutically acceptable salt or ester thereof is a nitrogen containing bisphosphonate or pharmaceutically acceptable salt thereof.
- the nitrogen containing bisphosphonate or pharmaceutically acceptable salt thereof is selected from the group consisting of:
- the nitrogen containing bisphosphonic acid or pharmaceutically acceptable salt thereof is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or a pharmaceutically acceptable salt thereof.
- the nitrogen containing bisphosphonic acid or pharmaceutically acceptable salt thereof is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.
- the present invention is also characterized by to pharmaceutical compositions comprising from about 0.5 to 40% by weight of an active ingredient, said active ingredient being a bisphosphonic acid or a pharmaceutically acceptable salt thereof; from about 60 to 99.5% by weight of excipients, said excipients comprising a diluent selected from the group consisting of anhydrous lactose or hydrous fast flow lactose, a binder, a disintegrant, a lubricant; and a discontinuous wax polish; wherein said pharmaceutical composition is in a desired tablet form.
- the bisphosphonic acid or pharmaceutically acceptable salt thereof is a nitrogen containing bisphosphonate or pharmaceutically acceptable salt thereof.
- the nitrogen containing bisphosphonate or pharmaceutically acceptable salt thereof is selected from the group consisting of:
- the nitrogen containing bisphosphonic acid or pharmaceutically acceptable salt thereof is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or a pharmaceutically acceptable salt thereof.
- the nitrogen containing bisphosphonic acid or pharmaceutically acceptable salt thereof is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.
- the present invention also relates to processes for the production of pharmaceutical compositions and tablets.
- the processes include coating the compositions or tablets with a discontinuous wax polish which provides advantages over completely coated compositions and tablets. Because the compositions or tablets are discontinuously coated, the bioavailability of the active ingredient is preserved.
- the present invention is also characterized by processes for the preparation of a tablet containing an active ingredient, said active ingredient being a bisphosphonic acid or a pharmaceutically acceptable salt thereof; which process comprises:
- a diluent selected from the group consisting of anhydrous lactose and hydrous fast flow lactose and mixtures thereof,
- the bisphosphonic acid or pharmaceutically acceptable salt thereof is a nitrogen containing bisphosphonate or pharmaceutically acceptable salt thereof.
- the nitrogen containing bisphosphonate or pharmaceutically acceptable salt thereof is selected from the group consisting of:
- the nitrogen containing bisphosphonic acid or pharmaceutically acceptable salt thereof is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or a pharmaceutically acceptable salt thereof.
- the nitrogen containing bisphosphonic acid or pharmaceutically acceptable salt thereof is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.
- the dry binder is microcrystalline cellulose.
- the disintegrant is selected from the group consisting of modified starch, modified cellulose polymer, and croscarmellose sodium, or a combination thereof.
- the disintegrant is croscarmellose sodium.
- the lubricant is magnesium stearate.
- the processes are carried out at ambient temperature.
- wax which had originally referred to relatively high melting animal or vegetable derived lipids, is applied to a large variety of chemically different lipids in modern parlance. Included as waxes are animal waxes, plant waxes, mineral waxes and petroleum waxes. See International Cosmetic Ingredient Dictionary and Handbook, Seventh Edition, vol. 1, p. 1604-05 (1997), which is hereby incorporated by reference in its entirety.
- the discontinuous wax polish is selected from the group consisting of: apple peel wax, avocado wax, bayberry wax, beeswax, candelilla wax, carnauba wax, ceresin, cetyl esters, hydrogenated jojoba oil, hydrogenated jojoba wax, hydrogenated microcrystalline wax, hydrogenated rice bran wax, hydrolyzed beeswax, jojoba butter, jojoba esters, jojoba wax, lanolin wax, microcrystalline wax, mink wax, montan acid wax, mantan wax, orange peel wax, ouricury wax, oxidized beeswax, oxidized microcrystalline wax, ozokerite, palm kernel wax, paraffin, PEG-6 Beeswax, PEG-8 Beeswax, PEG-12 Beeswax, PEG-20 Beeswax, PEG-12 Carnauba, potassium oxidized microcrystalline wax, rice wax, shellac wax, spent grain wax, sulfurized jojoba oil,
- the discontinuous wax polish is carnauba wax.
- Carnauba wax which is also known as brazil wax or caranda wax, is the hardest and highest melting of the waxes commonly used in pharmaceutical formulations. It can be used as an aqueous emulsion or a powder to polish tablets. See Handbook of Pharmaceutical Excipients, Second Edition, p. 552 (1994), which is hereby incorporated by reference in its entirety.
- Beeswax can be obtained naturally (yellow beeswax) or chemically bleached (white beeswax). Beeswax consists of 70-75% of a mixture of various esters of straight chain monohydric alcohols with even number carbon chains, the chief ester being myricyl palmitate. Beeswax is primarily used as a stiffening agent, an emulsifier, or a polishing agent for tablets. See Handbook of Pharmaceutical Excipients, Second Edition, p. 558-60 (1994).
- Microcrystalline wax which is also known as amorphous wax and petroleum ceresin, is used to modify the crystal structure of other waxes present in a mixture so that changes in crystal structure, which are usually exhibited over a period of time, do not occur. Microcrystalline wax also prevents blends of waxes from sweating or bleeding. See Handbook of Pharmaceutical Excipients, Second Edition, p. 554 (1994).
- Paraffin which is also known as hard wax, paraffinium solidum, and paraffinium durum, is a purified mixture of solid saturated hydrocarbons having the general formula C n H 2n +2. It is generally obtained from petroleum or shale oil. See Handbook of Pharmaceutical Excipients, Second Edition, p. 327 (1994).
- Cetyl esters wax which is also known as spermaceti wax replacement and synthetic spermaceti, is a mixture consisting primarily of esters of saturated fatty alcohols and saturated fatty acids. See Handbook of Pharmaceutical Excipients, Second Edition, p. 104(1994).
- Shellac wax which is also known as lacca and lac, is a naturally occurring material that is used in pharmaceutical formulations for the coating of tablets.
- Shellac wax is usually applied as a 35% w/v alcoholic solution, but is also applied as a 40% w/v alcoholic solution when sealing tablets to protect them from moisture before being film or sugar coated.
- Shellac is insoluble in acidic conditions but soluble at higher pHs. See Handbook of Pharmaceutical Excipients, Second Edition, p. 422-23 (1994).
- the pharmaceutical compositions and tablets of the present invention are generally administered to mammals in need of bisphosphonate therapy.
- the mammals are human patients, particularly human patients in need of inhibiting bone resorption, such as patients in need of treating or preventing abnormal bone resorption.
- compositions and tablets of the present invention are especially useful in administering bisphosphonate therapy to human patients that have been identified as suffering from or are susceptible to upper gastrointestinal disorders, e.g. GERD, esophagitis, dyspepsia, ulcers, etc. In such patients conventional bisphosphonate therapy could potentially exacerbate or induce such upper gastrointestinal disorders.
- upper gastrointestinal disorders e.g. GERD, esophagitis, dyspepsia, ulcers, etc.
- conventional bisphosphonate therapy could potentially exacerbate or induce such upper gastrointestinal disorders.
- discontinuous wax polish means a wax polish that is not continuously applied to the surface area of a pharmaceutical tablet. Accordingly, the wax polish is applied to the pharmaceutical tablet such that about 1 to 99% of the surface area of the tablet is coated with wax polish.
- pharmaceutical tablet means a solid dosage form that contains a excipients and a pharmaceutically effective amount of bisphosphonate compound that will elicit the desired therapeutic effect or response when administered in accordance with the desired treatment regimen.
- surface area means the exterior area of a pharmaceutical tablet.
- pharmaceutically effective amount means that amount of the bisphosphonate compound, that will elicit the desired therapeutic effect or response when administered in accordance with the desired treatment regimen.
- a preferred pharmaceutically effective amount of the bisphosphonate is a bone resorption inhibiting amount.
- the term “minimize the occurrence of or potential for adverse gastrointestinal effects”, as used herein, means reducing, preventing, decreasing, or lessening the occurrence of or the potential for incurring unwanted side effects in the gastrointestinal tract, i.e. the esophagus, stomach, intestines, and rectum, particularly the upper gastrointestinal tract, i.e. the esophagus and stomach.
- Non-limiting adverse gastrointestinal effects include, but are not limited to GERD, esophagitis, dyspepsia, ulcers, esophageal irritation, esophageal perforation, abdominal pain, and constipation.
- salts and derivatives of the bisphosphonates have the same general pharmacological properties as the free acid form from which they are derived and are acceptable from a toxicity viewpoint.
- salts refers to non-toxic salts of the compounds useful in the instant invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
- Representative salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methyl
- suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
- Pharmaceutically acceptable salts also specifically include hydrates as well as the anhydrous forms.
- Dosage regimens utilizing the compounds of the present invention are selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient or subject; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient or subject; and the particular compound or salt thereof employed.
- An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to reduce the risk of, counter or arrest the progress of the condition.
- Oral dosages of the present invention when used for the indicated effects, will range between about 0.05 mg per kg of body weight per day (mg/kg/day) to about 1.0 mg/kg/day.
- alendronate would be administered to mammals in preferred doses of about 2.5 mg to about 50 mg daily, preferably about 5 mg for osteoporosis treatment and about 10 mg for osteoporosis prevention, and about 40 mg Paget's disease.
- Preferred weekly dosages are about 35 mg, e.g., for osteoporosis prevention and about 70 mg, e.g., for osteoporosis treatment.
- Preferred twice-weekly dosage are about 17.5 mg, e.g., for osteoporosis prevention and about 35 mg, e.g., for osteoporosis treatment.
- the dosages may be varied over time, such that a patient may receive a high dose, such as 20 mg/day for a treatment period, such as two years, followed by a lower dose thereafter, such as 5 mg/day thereafter.
- a low dose i.e. approximately 5 mg
- Oral doses of the present invention can be administered in a single daily dose or in a divided dose.
- compositions of the present invention comprise the administration of a bisphosphonate or a pharmaceutically acceptable salt thereof.
- the bisphosphonates of the present invention correspond to the chemical formula
- n is an integer from 0 to 7 and wherein A and X are independently selected from the group consisting of H, OH, halogen, NH 2 , SH, phenyl, C1-C30 alkyl, C3-C30 branched or cycloalkyl, C1-C30 substituted alkyl, C1-C10 alkyl substituted NH 2 , C3-C10 branched or cycloalkyl substituted NH 2 , C1-C10 dialkyl substituted NH 2 , C1-C10 alkoxy, C1-C10 alkyl substituted thio, thiophenyl, halophenylthio, C1-C10 alkyl substituted phenyl, pyridyl, furanyl, pyrrolidinyl, imidazolyl, imidazopyridinyl, and benzyl, such that both A and X are not selected from H or OH when n is
- the alkyl groups can be straight, branched, or cyclic, provided sufficient atoms are selected for the chemical formula.
- the C1-C30 substituted alkyl can include a wide variety of substituents, non-limiting examples which include those selected from the group consisting of phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, NH 2 , C1-C10 alkyl or dialkyl substituted NH 2 , OH, SH, and C 1 -C10 alkoxy.
- the foregoing chemical formula is also intended to encompass complex carbocyclic, aromatic and hetero atom structures for the A and/or X substituents, non-limiting examples of which include naphthyl, quinolyl, isoquinolyl, adamantyl, and chlorophenylthio.
- a non-limiting class of structures useful in the instant invention are those in which A is selected from the group consisting of H, OH, and halogen, and X is selected from the group consisting of C1-C30 alkyl, C1-C30 substituted alkyl, halogen, and C1-C10 alkyl or phenyl substituted thio.
- a non-limiting subclass of structures useful in the instant invention are those in which A is selected from the group consisting of H, OH, and Cl, and X is selected from the group consisting of C1-C30 alkyl, C1-C30 substituted alkyl, Cl, and chlorophenylthio.
- a non-limiting example of the subclass of structures useful in the instant invention is when A is OH, X is a 3-aminopropyl moiety and n is zero, so that the resulting compound is a 4-amino-1,-hydroxybutylidene-1,1-bisphosphonate, i.e. alendronate.
- salts and derivatives of the bisphosphonates are also useful herein.
- Non-limiting examples of salts include those selected from the group consisting alkali metal, alkaline metal, ammonium, and mono-, DI, tri-, or tetra-C1-C30-alkyl-substituted ammonium.
- Preferred salts are those selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.
- derivatives include those selected from the group consisting of esters, hydrates, and amides.
- bisphosphonate and “bisphosphonates”, as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates, biphosphonic acids, and diphosphonic acids, as well as salts and derivatives of these materials.
- the use of a specific nomenclature in referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated. Because of the mixed nomenclature currently in use by those or ordinary skill in the art, reference to a specific weight or percentage of a bisphosphonate compound in the present invention is on an acid active weight basis, unless indicated otherwise herein.
- the phrase “about 5 mg of a bone resorption inhibiting bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof, on an alendronic acid active weight basis” means that the amount of the bisphosphonate compound selected is calculated based on 5 mg of alendronic acid.
- Non-limiting examples of bisphosphonates useful herein include the following:
- Alendronate also known as alendronate sodium or alendronate monosodium trihydrate
- 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium trihydrate 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium trihydrate.
- a non-limiting class of bisphosphonates useful in the instant invention are selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
- a non-limiting subclass of the above-mentioned class useful in the instant case contains alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
- a non-limiting example of the subclass is alendronate monosodium trihydrate.
- the compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, pastes, gels, solutions, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (e.g., ocular eyedrop), subcutaneous, intramuscular or transdermal (e.g., patch) form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as a treatment for dental resorptive lesions.
- compositions useful in the present invention comprise a pharmaceutically effective amount of a bisphosphonate or a pharmaceutically acceptable salt thereof.
- the bisphosphonate is typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers, collectively referred to herein as “carrier materials”, suitably selected with respect to oral administration, i.e. tablets, capsules, elixirs, syrups, effervescent compositions, powders, and the like, and consistent with conventional pharmaceutical practices.
- the active ingredient can be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like;
- an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like
- the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders can include starch, gelatin, natural sugars such a glucose, anhydrous lactose, free-flow lactose, beta-lactose, and corn sweeteners, natural and synthetic gums, such as acacia, guar, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- a tablet formulations for alendronate monosodium trihydrate and other bisphosphonates are described in U.S. Pat. No. 5,358,941, to Bechard et al, issued Oct. 25, 1994, and U.S. Pat. No. 5,681,590, to Bechard et al., issued Oct. 28, 1997, which are both incorporated by reference herein in its entirety.
- Oral liquid alendronate formulations are described in U.S. Pat. No. 5,462,932, to Brenner et al, issued Oct. 31, 1995, which is incorporated by reference herein in its entirety.
- Intravenous alendronate formulations are described in U.S. Pat. No. 5,780,455, to Brenner et al, issued Jul.
- the compounds used in the present method can also be coupled with soluble polymers as targetable drug carriers.
- soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxylpropyl-methacrylamide, and the like.
- the precise dosage of the bisphonate will vary with the dosing schedule, the oral potency of the particular bisphosphonate chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors.
- a precise pharmaceutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician.
- Appropriate amounts can be determined by routine experimentation from animal models and human clinical studies.
- an appropriate amount of bisphosphonate is chosen to obtain a dental resorptive lesion inhibiting effect.
- Tablets are prepared using standard mixing and formation techniques as described in U.S. Pat. No. 5,358,941, to Bechard et al., issued Oct. 25, 1994, which is incorporated by reference herein in its entirety.
- the tablets are polished with a discontinuous film of the desired wax using a coating pan, a coating column, a blender, or equivalent equipment.
- tablets containing about 10 mg or 70 mg of alendronate monosodium trihydrate, on an alendronic acid active basis are prepared using the following relative weights of ingredients. 10 mg Tablet 70 mg Tablet Ingredient Per Tablet Per Tablet Alendronate Monosodium 13.05 mg 91.37 mg Trihydrate Anhydrous Lactose, NF 104 mg 114 mg Microcrystalline Cellulose, 80 mg 140 mg NF Magnesium Stearate, NF 1 mg 1.75 mg Croscarmellose Sodium, NF 2 mg 3.5 mg Carnauba Wax 0.2 mg 0.2 mg
- the resulting tablets are useful for administration in accordance with the methods of the present invention for inhibiting bone resorption.
- tablets comprising other relative weights of alendronate, on an alendronic acid active basis are prepared: e.g., tablets containing about 5, 8.75, 17.5, 35 and 140 mg per tablet.
- tablets containing other bisphosphonates at appropriate active levels are similarly prepared: e.g., cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, and pharmaceutically acceptable salts thereof.
- tablets containing combinations of bisphosphonates are similarly prepared.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/881,285 US20010036475A1 (en) | 1999-07-01 | 2001-06-14 | Pharmaceutical tablets |
US10/099,672 US6623755B2 (en) | 1999-07-01 | 2002-03-15 | Pharmaceutical tablets |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14198799P | 1999-07-01 | 1999-07-01 | |
US60551300A | 2000-06-28 | 2000-06-28 | |
US09/881,285 US20010036475A1 (en) | 1999-07-01 | 2001-06-14 | Pharmaceutical tablets |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US60551300A Continuation | 1999-07-01 | 2000-06-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/099,672 Continuation US6623755B2 (en) | 1999-07-01 | 2002-03-15 | Pharmaceutical tablets |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010036475A1 true US20010036475A1 (en) | 2001-11-01 |
Family
ID=22498098
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/881,285 Abandoned US20010036475A1 (en) | 1999-07-01 | 2001-06-14 | Pharmaceutical tablets |
US10/099,672 Expired - Fee Related US6623755B2 (en) | 1999-07-01 | 2002-03-15 | Pharmaceutical tablets |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/099,672 Expired - Fee Related US6623755B2 (en) | 1999-07-01 | 2002-03-15 | Pharmaceutical tablets |
Country Status (11)
Country | Link |
---|---|
US (2) | US20010036475A1 (ja) |
EP (1) | EP1196175A1 (ja) |
JP (1) | JP2003503460A (ja) |
KR (1) | KR20020015063A (ja) |
AR (1) | AR024462A1 (ja) |
AU (1) | AU6055400A (ja) |
CA (1) | CA2378521A1 (ja) |
HK (1) | HK1041816A1 (ja) |
IL (1) | IL146632A0 (ja) |
NZ (1) | NZ515614A (ja) |
WO (1) | WO2001001991A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
US20050112202A1 (en) * | 2001-12-24 | 2005-05-26 | Lerner E. I. | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
US20050260262A1 (en) * | 2004-05-24 | 2005-11-24 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20060110452A1 (en) * | 2004-05-24 | 2006-05-25 | The Procter & Gamble Company | Dosage forms of risedronate |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US20100113394A1 (en) * | 2004-05-24 | 2010-05-06 | Warner Chilcott Company, Llc. | Low dosage forms of risedronate or its salts |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE376444T1 (de) | 2002-05-10 | 2007-11-15 | Hoffmann La Roche | Ibandronsäure zur behandlung und vorbeugung von osteoporose |
BR0309691A (pt) | 2002-12-20 | 2005-08-02 | Hoffmann La Roche | Formulação de ibandronato em alta dose |
US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
GB0616794D0 (en) | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
US20080139514A1 (en) * | 2006-11-29 | 2008-06-12 | Subhash Pandurang Gore | Diphosphonic acid pharmaceutical compositions |
KR20100014090A (ko) * | 2008-08-01 | 2010-02-10 | 동화약품주식회사 | 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물 |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US9711456B2 (en) | 2015-12-19 | 2017-07-18 | International Business Machines Corporation | Composite manganese nitride/low-K dielectric cap |
EP3544614A4 (en) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | ORAL TESTOSTERONE UNDECANOATE THERAPY |
EP3918007A1 (de) * | 2019-01-28 | 2021-12-08 | Katjes Fassin GmbH. + Co. Kommanditgesellschaft | Apfelwachs-beinhaltende zusammensetzungen |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1036368A (en) | 1963-10-31 | 1966-07-20 | Nat Dairy Prod Corp | Method for the manufacture of lactose-containing tablets |
DE2534391C2 (de) | 1975-08-01 | 1983-01-13 | Henkel KGaA, 4000 Düsseldorf | 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren |
DE2745083C2 (de) | 1977-10-07 | 1985-05-02 | Henkel KGaA, 4000 Düsseldorf | Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung |
IT1201087B (it) | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
JPH07100665B2 (ja) | 1987-12-23 | 1995-11-01 | 信越化学工業株式会社 | 被覆薬剤の製造方法 |
CA1339805C (en) | 1988-01-20 | 1998-04-07 | Yasuo Isomura | (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active |
US5047246A (en) | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
JP2525478B2 (ja) | 1989-03-01 | 1996-08-21 | 帝人株式会社 | 安定性の改良された活性型ビタミンd▲下3▼類固型製剤 |
US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
JP3411690B2 (ja) * | 1994-09-21 | 2003-06-03 | 帝人株式会社 | 局所投与用アレンドロン酸ナトリウム製剤 |
DE19615812A1 (de) * | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
US6190591B1 (en) * | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
NZ503946A (en) | 1997-06-11 | 2003-02-28 | Procter & Gamble | Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments |
KR100336090B1 (ko) * | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
-
2000
- 2000-06-23 AR ARP000103154A patent/AR024462A1/es not_active Application Discontinuation
- 2000-06-27 AU AU60554/00A patent/AU6055400A/en not_active Abandoned
- 2000-06-27 KR KR1020017016729A patent/KR20020015063A/ko not_active Application Discontinuation
- 2000-06-27 WO PCT/US2000/017569 patent/WO2001001991A1/en not_active Application Discontinuation
- 2000-06-27 CA CA002378521A patent/CA2378521A1/en not_active Abandoned
- 2000-06-27 NZ NZ515614A patent/NZ515614A/xx not_active Application Discontinuation
- 2000-06-27 EP EP00946859A patent/EP1196175A1/en not_active Withdrawn
- 2000-06-27 JP JP2001507483A patent/JP2003503460A/ja not_active Withdrawn
- 2000-06-27 IL IL14663200A patent/IL146632A0/xx unknown
-
2001
- 2001-06-14 US US09/881,285 patent/US20010036475A1/en not_active Abandoned
-
2002
- 2002-03-15 US US10/099,672 patent/US6623755B2/en not_active Expired - Fee Related
- 2002-05-08 HK HK02103495.2A patent/HK1041816A1/zh unknown
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7611722B2 (en) | 2001-12-24 | 2009-11-03 | Teva Pharmaceutical Industries Ltd. | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
US20050112202A1 (en) * | 2001-12-24 | 2005-05-26 | Lerner E. I. | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
EP2172192A1 (en) | 2001-12-24 | 2010-04-07 | Teva Pharmaceutical Industries Ltd. | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder of granular material, and process and tooling for producing it |
US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
US20060233879A1 (en) * | 2001-12-24 | 2006-10-19 | Teva Pharmaceutical Industries Ltd. | Controlled released dosage forms |
US20060233880A1 (en) * | 2001-12-24 | 2006-10-19 | Teva Pharmaceutical Industries Ltd. | Controlled release dosage forms |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US20060110452A1 (en) * | 2004-05-24 | 2006-05-25 | The Procter & Gamble Company | Dosage forms of risedronate |
US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20050260262A1 (en) * | 2004-05-24 | 2005-11-24 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20100113394A1 (en) * | 2004-05-24 | 2010-05-06 | Warner Chilcott Company, Llc. | Low dosage forms of risedronate or its salts |
US20100113395A1 (en) * | 2004-05-24 | 2010-05-06 | Warner Chilcott Company, Llc. | Low dosage forms of risedronate or its salts |
US20100119559A1 (en) * | 2004-05-24 | 2010-05-13 | Warner Chilcott Company, Llc. | Dosage forms of risedronate |
US8246989B2 (en) | 2004-05-24 | 2012-08-21 | Warner Chilcott Company, Llc | Dosage forms of bisphosphonates |
US8409615B2 (en) | 2004-05-24 | 2013-04-02 | Warner Chilcott Company, Llc | Low dosage forms of risedronate or its salts |
US8409614B2 (en) | 2004-05-24 | 2013-04-02 | Warner Chilcott Company, Llc | Low dosage forms of risedronate or its salts |
US8535718B2 (en) | 2004-05-24 | 2013-09-17 | Warner Chilcott Company, Llc. | Dosage forms of bisphosphonates |
Also Published As
Publication number | Publication date |
---|---|
WO2001001991A1 (en) | 2001-01-11 |
AR024462A1 (es) | 2002-10-02 |
NZ515614A (en) | 2004-01-30 |
US20020187186A1 (en) | 2002-12-12 |
US6623755B2 (en) | 2003-09-23 |
HK1041816A1 (zh) | 2002-07-26 |
AU6055400A (en) | 2001-01-22 |
JP2003503460A (ja) | 2003-01-28 |
CA2378521A1 (en) | 2001-01-11 |
EP1196175A1 (en) | 2002-04-17 |
IL146632A0 (en) | 2002-07-25 |
KR20020015063A (ko) | 2002-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6623755B2 (en) | Pharmaceutical tablets | |
US6333316B1 (en) | Method for inhibiting bone resorption | |
US6015801A (en) | Method for inhibiting bone resorption | |
US6465443B2 (en) | Method for inhibiting bone resorption | |
JP2002529490A (ja) | 歯牙吸収性病変の阻害方法 | |
CA2294595C (en) | Inhibiting bone resorption | |
US20040180862A1 (en) | Compositions and methods for inhibiting bone resorption | |
AU741818B2 (en) | Method for inhibiting bone resorption | |
CA2349744A1 (en) | Inhibition bone resorption | |
IL153109A (en) | An effective pharmaceutical composition for inhibiting bone resorption in humans containing alendronic acid or its acceptable pharmaceutical salt or mixture | |
HRP20000035A2 (en) | Method for inhibiting bone resorption | |
AU2451102A (en) | Method for inhibiting bone resorption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |